Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
LEBANON, N.H. Jan. 13, 2026 /PRNewswire/ -- Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 11 new programs entered clinical trials in 2025. These 11 programs bring the total number of partner programs that have entered clinical trials to 89, including six therapeutic products containing molecules discovered or optimized using the Adimab platform which have been authorized for commercial sale. Partners with new clinical programs in 2025 include Abogen, GSK, iTeos, Innovent, Invivyd, Kelonia Therapeutics, and Triveni Bio, among others. Adimab's latest partner program to receive approval is GSK's Exdensur (depemokimab), approved in the US for the treatment of severe asthma with an eosinophilic phenotype and in the UK and Japan for two indications: (severe) asthma and CRSwNP. Other commercial products containing molecules from Adimab include: Innovent's TYVYT ® (sintilimab injection), a
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- ?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]Yahoo! Finance
- Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]Yahoo! Finance
- Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business HighlightsGlobeNewswire
- BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]Yahoo! Finance
- Does Invivyd's (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 11/6/25 - Miss
IVVD
Sec Filings
- 1/8/26 - Form 8-K
- 12/29/25 - Form SCHEDULE
- 12/29/25 - Form EFFECT
- IVVD's page on the SEC website